The Trump administration’s FY 2027 budget proposal seeks to move 340B program oversight from HRSA to CMS, while significantly increasing its funding. This move could signal a major shift in federal drug pricing policy, reports 340B Report. The proposed reorganization, which includes a 68% funding increase to $20.5 million for the Office of Pharmacy Affairs […]